Ivan Dimov is a rare blend of scientist, inventor, and entrepreneur. He’s built mobile tech from scratch, developed diagnostic tools in academic labs, and co-founded the company that brought the first FDA-authorized at-home COVID-19 test to market. Along the way, he’s led research at Stanford, launched robotics and hospital tech centers in Chile, and amassed more than 40 patents.
Now, as co-founder and CEO of Orca Bio, which he launched in 2016, Ivan is channeling his deep scientific and entrepreneurial background into building a new generation of precision-engineered cell therapies. His experience spans industries and continents, but his focus has always been the same: patient impact.
Ivan didn’t start Orca Bio with a product–he started it with a problem. He saw that existing cell therapies lacked precision, limiting their effectiveness and scalability. So he set out to build something different: a new class of high-precision therapies designed to consistently and safely treat patients with blood cancers and autoimmune diseases.
Ivan is the first to admit the process is messy–especially when building at the edge of what science can deliver. He emphasizes the need for stubbornness to stick with your vision, and the self-awareness to course-correct along the way. That balance is what defines him as a leader–and it’s what continues to push Orca Bio beyond the limits of traditional cell therapy.
